Antinuclear Antibody Testing Dilemmas
Autoantibodies have been used as a biomarker for systemic autoimmune rheumatic diseases for more than a half-century and have found a solid place as a tool in diagnosing conditions such as systemic lupus erythematosus, scleroderma, and Sjögren syndrome. Recently, however, evolving technologies and inadequate understanding of the limitations of various methods have led antinuclear antibody (ANA) results to be used inappropriately as a screening test for systemic autoimmune rheumatic diseases. Given this challenge, laboratorians have a responsibility to know the ins-and-outs of their methods and educate physicians to make the best use of ANA testing, according to experts.
Does High Throughput Trump Sensitivity?
Topics of this artice:
- The Pros and Cons of Immunofluorescence
- What’s in the Pattern?
- Technological, Standardization Advances
- The Move to Higher Throughput
- What’s it Missing?
- IIF: Still the Gold Standard
- Wading Through Testing Challenges
November 2011 Clinical Laboratory News: Antinuclear Antibody Testing Dilemmas
Learn more and strengthen your expertise
External quality assessment schemes (EQA) for Immunology diagnostics